WEST CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Zelos Therapeutics, Inc., today announced top-line results from a Phase 2 study of its novel parathyroid hormone (PTH) analogue, Ostabolin-C™, in postmenopausal women with osteoporosis. Ostabolin-C is cyclic PTH (1-31), a proprietary PTH analogue that has demonstrated strong bone building activity in preclinical studies and is in late stage clinical development for the treatment of osteoporosis.
